Women’s Health Market (Treatment Type - Hormonal Treatment (Estrogen Therapy, Progestin Therapy, Combination Therapy, Thyroid Replacement Therapy, Parathyroid Hormone Therapy, and Others) and Non-Hormonal Treatment (Targeted Therapy Drugs, Antibiotics, Bisphosphonates, and Others); Disease Indication - Cancer (Breast Cancer, Cervical Cancer, Ovarian Cancer), Hypothyroidism, Post-Menopausal Syndrome, Osteoporosis, Contraceptive, Uterine Fibroid, Urinary Tract Infection, and Others)- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

1. Preface 
     1.1. Report Scope and Market Segmentation 
     1.2. Research Highlights

2. Assumptions and Research Methodology 
     2.1. Assumptions
     2.2. Acronyms Used
     2.3. Research Methodology

3. Executive Summary
     3.1. Global Women’s Health Market Snapshot

4. Market Overview
     4.1. Market Overview
     4.2. Market Opportunity Map 
     4.3. Key Industry Events
     4.4. Global Women’s Health Market Size (US$ Mn) Forecast, 2017–2030
     4.5. Global Women’s Health Market Outlook
     4.6. Pipeline Analysis
     4.7. Key Trends
     4.8. Government Initiatives/Key Investments Assessment

5. Market Dynamics
     5.1. Drivers and Restraints Snapshot Analysis
     5.2. Drivers
     5.3. Restraints
     5.4. Opportunities

6. Global Women’s Health Market Analysis, by Treatment Type
     6.1. Introduction
     6.2. Key Insights
     6.3. Global Women’s Health Market Value Share Analysis, by Treatment Type
     6.4. Global Women’s Health Market Forecast, by Treatment Type
             6.4.1. Hormonal
                     6.4.1.1. Estrogen
                     6.4.1.2. Progestin
                     6.4.1.3. Combination
                     6.4.1.4. Parathyroid
                     6.4.1.5. Thyroid
                     6.4.1.6. Others
             6.4.2. Non-Hormonal
                     6.4.2.1. Targeted Drugs
                     6.4.2.2. Antibiotics
                     6.4.2.3. Biphosphonates
                     6.4.2.4. Others
     6.5. Global Women’s Health Market Attractiveness Analysis, by Treatment Type
     6.6. Key Trends

7. Global Women’s Health Market Analysis, by Disease Indication
     7.1. Introduction
     7.2. Key Insights
     7.3. Global Women’s Health Market Value Share Analysis, by Treatment Type
     7.4. Global Women’s Health Market Forecast, by Treatment Type
             7.4.1. Cancer
                     7.4.1.1. Breast Cancer
                     7.4.1.2. Cervical Cancer
                     7.4.1.3. Ovarian Cancer
             7.4.2. Hypothyroidism
             7.4.3. Menopause
             7.4.4. Osteoporosis
             7.4.5. Contraceptive
             7.4.6. Uterine Fibroid
             7.4.7. Urinary Tract Infection
     7.5. Global Women’s Health Market Attractiveness Analysis, by Treatment Type
     7.6. Key Trends

8. Global Women’s Health Market Analysis, by Region
     8.1. Global Women’s Health Market Value Share Analysis, by Region 
     8.2. Global Women’s Health Market Forecast, by Region, 2017–2030 
             8.2.1. North America
             8.2.2. Europe
             8.2.3. Asia Pacific
             8.2.4. Latin America
             8.2.5. Middle East & Africa

9. North America Women’s Health Market Analysis
     9.1. North America Women’s Health Market Overview
     9.2. North America Women’s Health Market Value Share Analysis, by Treatment Type
     9.3. North America Women’s Health Market Value Share Analysis, by Disease Indication
     9.4. North America Women’s Health Market Value Share Analysis, by Country
     9.5. North America Women’s Health Market Forecast, by Treatment Type
             9.5.1. Hormonal
                     9.5.1.1. Estrogen
                     9.5.1.2. Progestin
                     9.5.1.3. Combination
                     9.5.1.4. Parathyroid
                     9.5.1.5. Thyroid
                     9.5.1.6. Others
             9.5.2. Non-Hormonal
                     9.5.2.1. Targeted Drugs
                     9.5.2.2. Antibiotics
                     9.5.2.3. Biphosphonates
                     9.5.2.4. Others
     9.6. North America Women’s Health Market Forecast, by Disease Indication
             9.6.1. Cancer
                     9.6.1.1. Breast Cancer
                     9.6.1.2. Cervical Cancer
                     9.6.1.3. Ovarian Cancer
             9.6.2. Hypothyroidism
             9.6.3. Menopause
             9.6.4. Osteoporosis
             9.6.5. Contraceptive
             9.6.6. Uterine Fibroid
             9.6.7. Urinary Tract Infection
     9.7. North America Women’s Health Market Forecast, by Country
             9.7.1. United States
             9.7.2. Canada
     9.8. North America Women’s Health Market Attractiveness Analysis, 
             9.8.1. By Treatment Type 
             9.8.2.  By Disease Indication 
             9.8.3.  By Country
     9.9. North America – Key Trends

10. Europe Women’s Health Market Analysis
     10.1. Europe Women’s Health Market Overview
     10.2. Europe Women’s Health Market Value Share Analysis, by Treatment Type
     10.3. Europe Women’s Health Market Value Share Analysis, by Disease Indication
     10.4. Europe Women’s Health Market Value Share Analysis, by Country
     10.5. Europe Women’s Health Market Forecast, by Treatment Type
             10.5.1. Hormonal
                     10.5.1.1. Estrogen
                     10.5.1.2. Progestin
                     10.5.1.3. Combination
                     10.5.1.4. Parathyroid
                     10.5.1.5. Thyroid
                     10.5.1.6. Others
             10.5.2. Non-Hormonal
                     10.5.2.1. Targeted Drugs
                     10.5.2.2. Antibiotics
                     10.5.2.3. Biphosphonates
                     10.5.2.4. Others
     10.6. Europe Women’s Health Market Forecast, by Disease Indication
             10.6.1. Cancer
                     10.6.1.1. Breast Cancer
                     10.6.1.2. Cervical Cancer
                     10.6.1.3. Ovarian Cancer
             10.6.2. Hypothyroidism
             10.6.3. Menopause
             10.6.4. Osteoporosis
             10.6.5. Contraceptive
             10.6.6. Uterine Fibroid
             10.6.7. Urinary Tract Infection
     10.7. Europe Women’s Health Market Forecast, by Country / Sub-region
             10.7.1. UK
             10.7.2. Germany
             10.7.3. France
             10.7.4. Italy
             10.7.5. Spain
             10.7.6. Rest of Europe
     10.8. Europe Women’s Health Market Attractiveness Analysis 
             10.8.1. By Treatment Type
             10.8.2. By Disease Indication 
             10.8.3. By Country / Sub-region
     10.9. Europe – Key Trends

11. Asia Pacific Women’s Health Market Analysis
     11.1. Asia Pacific Women’s Health Market Overview
     11.2. Asia Pacific Women’s Health Market Value Share Analysis, by Treatment Type
     11.3. Asia Pacific Women’s Health Market Value Share Analysis, by Disease Indication
     11.4. Asia Pacific Women’s Health Market Value Share Analysis, by Country
     11.5. Asia Pacific Women’s Health Market Forecast, by Treatment Type
             11.5.1. Hormonal
                     11.5.1.1. Estrogen
                     11.5.1.2. Progestin
                     11.5.1.3. Combination
                     11.5.1.4. Parathyroid
                     11.5.1.5. Thyroid
                     11.5.1.6. Others
             11.5.2. Non-Hormonal
                     11.5.2.1. Targeted Drugs
                     11.5.2.2. Antibiotics
                     11.5.2.3. Biphosphonates
                     11.5.2.4. Others
     11.6. Asia Pacific Women’s Health Market Forecast, by Disease Indication
             11.6.1. Cancer
                     11.6.1.1. Breast Cancer
                     11.6.1.2. Cervical Cancer
                     11.6.1.3. Ovarian Cancer
             11.6.2. Hypothyroidism
             11.6.3. Menopause
             11.6.4. Osteoporosis
             11.6.5. Contraceptive
             11.6.6. Uterine Fibroid
             11.6.7. Urinary Tract Infection
     11.7. Asia Pacific Women’s Health Market Forecast, by Country / Sub-region
             11.7.1. China
             11.7.2. Japan
             11.7.3. India
             11.7.4. Australia
             11.7.5. Rest of APAC
     11.8. Asia Pacific Women’s Health Market Attractiveness Analysis
             11.8.1. By Treatment Type 
             11.8.2. By Disease Indication 
             11.8.3. By Country / Sub-region
     11.9. Asia Pacific – Key Trends

12. Latin America Women’s Health Market Analysis
     12.1. Latin America Women’s Health Market Overview
     12.2. Latin America Women’s Health Market Value Share Analysis, by Treatment Type
     12.3. Latin America Women’s Health Market Value Share Analysis, by Disease Indication
     12.4. Latin America Women’s Health Market Value Share Analysis, by Country
     12.5. Latin America Women’s Health Market Forecast, by Treatment Type
             12.5.1. Hormonal
                     12.5.1.1. Estrogen
                     12.5.1.2. Progestin
                     12.5.1.3. Combination
                     12.5.1.4. Parathyroid
                     12.5.1.5. Thyroid
                     12.5.1.6. Others
             12.5.2. Non-Hormonal
                     12.5.2.1. Targeted Drugs
                     12.5.2.2. Antibiotics
                     12.5.2.3. Biphosphonates
                     12.5.2.4. Others
     12.6. Latin America Women’s Health Market Forecast, by Disease Indication
             12.6.1. Cancer
                     12.6.1.1. Breast Cancer
                     12.6.1.2. Cervical Cancer
                     12.6.1.3. Ovarian Cancer
             12.6.2. Hypothyroidism
             12.6.3. Menopause
             12.6.4. Osteoporosis
             12.6.5. Contraceptive
             12.6.6. Uterine Fibroid
             12.6.7. Urinary Tract Infection
     12.7. Latin America Women’s Health Market Forecast, by Country / Sub-region
             12.7.1. Brazil
             12.7.2. Mexico
             12.7.3. Rest of Latin America
     12.8. Latin America Women’s Health Market Attractiveness Analysis
             12.8.1. By Treatment Type
             12.8.2. By Disease Indication
             12.8.3. By Country / Sub-region
     12.9. Latin America – Key Trends

13. Middle East & Africa Women’s Health Market Analysis
     13.1. Middle East & Africa Women’s Health Market Overview
     13.2. Middle East & Africa Women’s Health Market Value Share Analysis, by Treatment Type
     13.3. Middle East & Africa Women’s Health Market Value Share Analysis, by Disease Indication
     13.4. Middle East & Africa Women’s Health Market Value Share Analysis, by Country
     13.5. Middle East & Africa Women’s Health Market Forecast, by Treatment Type
             13.5.1. Hormonal
                     13.5.1.1. Estrogen
                     13.5.1.2. Progestin
                     13.5.1.3. Combination
                     13.5.1.4. Parathyroid
                     13.5.1.5. Thyroid
                     13.5.1.6. Others
             13.5.2. Non-Hormonal
                     13.5.2.1. Targeted Drugs
                     13.5.2.2. Antibiotics
                     13.5.2.3. Biphosphonates
                     13.5.2.4. Others
     13.6. Middle East & Africa Women’s Health Market Forecast, by Disease Indication
             13.6.1. Cancer
                     13.6.1.1. Breast Cancer
                     13.6.1.2. Cervical Cancer
                     13.6.1.3. Ovarian Cancer
             13.6.2. Hypothyroidism
             13.6.3. Menopause
             13.6.4. Osteoporosis
             13.6.5. Contraceptive
             13.6.6. Uterine Fibroid
             13.6.7. Urinary Tract Infection
     13.7. Middle East & Africa Women’s Health Market Forecast, by Country / Sub-region
             13.7.1. GCC Countries
             13.7.2. South Africa
             13.7.3. Rest of Middle East & Africa
     13.8. Middle East & Africa Women’s Health Market Attractiveness Analysis
             13.8.1. By Treatment Type
             13.8.2. By Disease Indication
             13.8.3. By Country / Sub-region
     13.9. Middle East & Africa – Key Trends

14. Competition Landscape
     14.1. Competitive Positioning
     14.2. Competition Matrix
     14.3. Company Profiles
             14.3.1. Eli Lilly and Company 
                     14.3.1.1. Overview (HQ, Employee Strength, Business Segments)
                     14.3.1.2. Financials
                     14.3.1.3. Recent Developments
                     14.3.1.4. Strategy
             14.3.2. Novartis AG
                     14.3.2.1. Overview (HQ, Employee Strength, Business Segments)
                     14.3.2.2. Financials
                     14.3.2.3. Recent Developments
                     14.3.2.4. Strategy
             14.3.3. Pfizer, Inc.
                     14.3.3.1. Overview (HQ, Employee Strength, Business Segments)
                     14.3.3.2. Financials
                     14.3.3.3. Recent Developments
                     14.3.3.4. Strategy
             14.3.4. Merck & Co., Inc.
                     14.3.4.1. Overview (HQ, Employee Strength, Business Segments)
                     14.3.4.2. Financials
                     14.3.4.3. Recent Developments
                     14.3.4.4. Strategy
             14.3.5. Novo Nordisk A/S 
                     14.3.5.1. Overview (HQ, Employee Strength, Business Segments)
                     14.3.5.2. Financials
                     14.3.5.3. Recent Developments
                     14.3.5.4. Strategy
             14.3.6. Amgen Inc. 
                     14.3.6.1. Overview (HQ, Employee Strength, Business Segments)
                     14.3.6.2. Financials
                     14.3.6.3. Recent Developments
                     14.3.6.4. Strategy
             14.3.7. AstraZeneca 
                     14.3.7.1. Overview (HQ, Employee Strength, Business Segments)
                     14.3.7.2. Financials
                     14.3.7.3. Recent Developments
                     14.3.7.4. Strategy
             14.3.8. F. Hoffmann-La Roche Ltd.
                     14.3.8.1. Overview (HQ, Employee Strength, Business Segments)
                     14.3.8.2. Financials
                     14.3.8.3. Recent Developments
                     14.3.8.4. Strategy
             14.3.9. Sanofi
                     14.3.9.1. Overview (HQ, Employee Strength, Business Segments)
                     14.3.9.2. Financials
                     14.3.9.3. Recent Developments
                     14.3.9.4. Strategy
             14.3.10. Allergan Plc
                     14.3.10.1. Overview (HQ, Employee Strength, Business Segments)
                     14.3.10.2. Financials
                     14.3.10.3. Recent Developments
                     14.3.10.4. Strategy
             14.3.11. GlaxoSmithKline plc
                     14.3.11.1. Overview (HQ, Employee Strength, Business Segments)
                     14.3.11.2. Financials
                     14.3.11.3. Recent Developments
                     14.3.11.4. Strategy
             14.3.12. Lupin Pharmaceuticals, Inc.
                     14.3.12.1. Overview (HQ, Employee Strength, Business Segments)
                     14.3.12.2. Financials
                     14.3.12.3. Recent Developments
                     14.3.12.4. Strategy